As people’s lifestyle and eating habits continue to change and the population ages, the incidence of diabetes is growing rapidly. The latest statistics show that the prevalence of diabetes in adults over 20 years of age in China is as high as 9.7%, with more than 92 million patients with the current disease. The diabetic population is at high risk for cardiovascular disease, with 80% of diabetics eventually dying from cardiovascular complications. Suffice it to say that if cardiovascular complications did not exist, diabetes would not be such a serious health problem. One of the main goals of treating diabetes is to prevent or reduce the occurrence of chronic complications of diabetes, especially cardiovascular and cerebrovascular pathologies. Studies have shown that the vast majority of acute cardiovascular events in diabetic patients are related to thrombosis, in which platelet function plays an important role. In vitro studies have shown that platelets in diabetic patients are extremely responsive to proplatelet aggregating agents, mainly due to a significant increase in thromboxane production. Aspirin inhibits platelet synthesis of thromboxane by blocking cyclooxygenase (COX), thereby inhibiting platelet aggregation and preventing thrombus formation. Many large clinical studies have confirmed that aspirin can effectively prevent cardiovascular and cerebrovascular events in diabetic patients, especially in the primary prevention of cardiovascular disease, and is recognized as the cornerstone of the prevention of cardiovascular and cerebrovascular events. So, do all diabetic patients need to take aspirin? What are its side effects? How exactly should it be regulated? Here are some questions about this. Aspirin is a double-edged sword, preventing the formation of blood clots and reducing cardiovascular events, but at the same time, it can also lead to an increased risk of bleeding, so it is important to carefully weigh the benefits and risks of aspirin. To regulate the use of aspirin, in 2010, the American Diabetes Association (ADA)/American Heart Association (AHA)/American College of Cardiology (ACC) published a joint statement on “The Use of Aspirin in the Primary Prevention of Cardiovascular Events in Patients with Diabetes,” which centered on first conducting a cardiovascular risk assessment of the diabetic population, fully considering the risk/benefit ratio, and ultimately To determine which patients with diabetes are appropriate candidates for aspirin for primary prevention of cardiovascular disease (primary prevention: a preventive strategy to avoid or reduce cardiovascular events by controlling cardiovascular risk factors through early intervention before the disease has developed or when the disease is in a subclinical stage).